ProMIS Neurosciences to Participate in 7th Annual Evercore HealthCONx Conference
ProMIS Neurosciences to Participate in 7th Annual Evercore HealthCONx Conference
ProMIS Neurosciences Inc. is a clinical stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company's proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. PMN310, the Company's lead product candidate for the treatment of AD, is a differentiated, humanized monoclonal antibody that has been designed to specifically bind toxic Aβ oligomers and to not bind plaque or monomers. Oligomers are known to drive disease progression in AD and PMN310 appears to be the only antibody to selectively bind oligomers, which is expected to support better safety and efficacy. PMN 310 has successfully completed a Phase 1a clinical study and ProMIS expects to initiate a Phase 1b clinical trial in AD patients by year end 2024. ProMIS has offices in Cambridge, Massachusetts and Toronto, Ontario.CAMBRIDGE, Massachusetts and TORONTO, Ontario, Nov. 26, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will participate in a fireside chat at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3, 2024 at 1:20 p.m. ET in Coral Gables, FL.
马萨诸塞州剑桥和安大略多伦多，2024年11月26日(GLOBE NEWSWIRE) -- 生物技术公司ProMIS Neurosciences Inc. (纳斯达克: PMN)，专注于针对神经退行性疾病如阿尔茨海默病(AD)、肌萎缩性侧索硬化症(ALS)和多系统萎缩(MSA)等疾病生成和开发抗体治疗药物的临床阶段公司，今日宣布ProMIS Neurosciences首席执行官Neil Warma将于2024年12月3日星期二美东时间下午1:20在佛罗里达州Coral Gables参加第七次年度Evercore HealthCONx大会的炉边聊天。
A live webcast of the fireside chat may be accessed by visiting the Events page of the Company's website at , and will be available for at least 30 days following the event.
可通过访问该公司网站的事件页面获取炉边聊天的现场网络直播，网址为 ，并将在活动结束后至少30天内提供。
About ProMIS Neurosciences Inc.
关于ProMIS Neurosciences Inc.
ProMIS Neurosciences Inc. is a clinical stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company's proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. PMN310, the Company's lead product candidate for the treatment of AD, is a differentiated, humanized monoclonal antibody that has been designed to specifically bind toxic Aβ oligomers and to not bind plaque or monomers. Oligomers are known to drive disease progression in AD and PMN310 appears to be the only antibody to selectively bind oligomers, which is expected to support better safety and efficacy. PMN 310 has successfully completed a Phase 1a clinical study and ProMIS expects to initiate a Phase 1b clinical trial in AD patients by year end 2024. ProMIS has offices in Cambridge, Massachusetts and Toronto, Ontario.
ProMIS Neurosciences Inc.是一家专注于生成和开发选择性靶向神经退行性疾病如阿尔茨海默病(AD)、肌萎缩性侧索硬化症(ALS)和多系统萎缩(MSA)中有毒错误折叠蛋白的抗体治疗的临床阶段生物技术公司。该公司的专有目标发现引擎应用热力学、计算发现平台——ProMIS和Collective Coordinates——以预测被称为特异疾病表位的新颖靶标，该表位位于错误折叠蛋白的分子表面。作为AD治疗的首选药物PMN310是一种不同凡响的人源化单克隆抗体，专门设计用于特异结合有毒的Aβ寡聚体且不与斑块或单体结合。寡聚体被认为驱动AD的疾病进展，PMN310似乎是唯一选择性结合寡聚体的抗体，这有望支持更好的安全性和疗效。PMN310已成功完成了一项1a期临床研究，ProMIS预计将于2024年年底启动针对AD患者的10亿期临床试验。ProMIS在马萨诸塞州剑桥和安大略多伦多设有办公室。
For further information:
进一步了解：
Visit us at .
请访问我们的网址.
Please submit media inquiries to info@promisneurosciences.com.
请将媒体咨询提交至 info@promisneurosciences.com.
For Investor Relations, please contact:
如需投资者关系，请联系：
Precision AQ (formerly Stern IR)
Anne Marie Fields, Managing Director
annemarie.fields@precisionaq.com
Tel. 212-362-1200
Precision AQ（前称Stern IR）
Anne Marie Fields，董事总经理
annemarie.fields@precisionaq.com
电话：212-362-1200
